Donglu Zhang
Pharmaceutical Candidate Optimization
Bristol-Myers Squibb
P.O. Box 4000
Princeton
USA
Name/email consistency: high
- Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Wang, L., Raghavan, N., He, K., Luettgen, J.M., Humphreys, W.G., Knabb, R.M., Pinto, D.J., Zhang, D. Drug Metab. Dispos. (2009)
- Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Zhang, D., He, K., Raghavan, N., Wang, L., Mitroka, J., Maxwell, B.D., Knabb, R.M., Frost, C., Schuster, A., Hao, F., Gu, Z., Humphreys, W.G., Grossman, S.J. Drug Metab. Dispos. (2009)
- Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs. Zhang, D., Raghavan, N., Chen, S.Y., Zhang, H., Quan, M., Lecureux, L., Patrone, L.M., Lam, P.Y., Bonacorsi, S.J., Knabb, R.M., Skiles, G.L., He, K. Drug Metab. Dispos. (2008)
- LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Zhang, D., Raghavan, N., Chando, T., Gambardella, J., Fu, Y., Zhang, D., Unger, S.E., Humphreys, W.G. Drug. Metab. Lett (2007)
- Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Zhang, D., Wang, L., Raghavan, N., Zhang, H., Li, W., Cheng, P.T., Yao, M., Zhang, L., Zhu, M., Bonacorsi, S., Yeola, S., Mitroka, J., Hariharan, N., Hosagrahara, V., Chandrasena, G., Shyu, W.C., Humphreys, W.G. Drug Metab. Dispos. (2007)
- Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Zhang, D., Wang, L., Chandrasena, G., Ma, L., Zhu, M., Zhang, H., Davis, C.D., Humphreys, W.G. Drug Metab. Dispos. (2007)
- Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards. Zhang, D., Zhang, H., Aranibar, N., Hanson, R., Huang, Y., Cheng, P.T., Wu, S., Bonacorsi, S., Zhu, M., Swaminathan, A., Humphreys, W.G. Drug Metab. Dispos. (2006)
- Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans. Zhang, D., Krishna, R., Wang, L., Zeng, J., Mitroka, J., Dai, R., Narasimhan, N., Reeves, R.A., Srinivas, N.R., Klunk, L.J. Drug Metab. Dispos. (2005)
- In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Zhang, D., Chando, T.J., Everett, D.W., Patten, C.J., Dehal, S.S., Humphreys, W.G. Drug Metab. Dispos. (2005)
- Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans. Zhang, D., Zhao, W., Roongta, V.A., Mitroka, J.G., Klunk, L.J., Zhu, M. Drug Metab. Dispos. (2004)
- Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats. Zhang, D., Ogan, M., Gedamke, R., Roongta, V., Dai, R., Zhu, M., Rinehart, J.K., Klunk, L., Mitroka, J. Drug Metab. Dispos. (2003)
